No Rest For The Pneumococcal Work Group: CDC Committee Readies For Merck’s V116

Merck’s 21-valent pneumococcal conjugate vaccine for older adults could see US FDA approval in H1 2024, opening up another level of complexity for the CDC’s vaccine recommendations.